Global Tyrosine Kinase JAK Inhibitors Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024


    Table of Contents

      1 Market Overview

      • 1.1 Tyrosine Kinase JAK Inhibitors Introduction
      • 1.2 Market Analysis by Type
        • 1.2.1 Tofacitinib
        • 1.2.2 Ruxolitinib
        • 1.2.3 Baricitinib
      • 1.3 Market Analysis by Applications
        • 1.3.1 Rheumatoid Arthritis (RA)
        • 1.3.2 Polycythemia Vera (PCV)
        • 1.3.3 Myelofibrosis (MF)
        • 1.3.4 Others
      • 1.4 Market Analysis by Regions
        • 1.4.1 North America (United States, Canada and Mexico)
          • 1.4.1.1 United States Market States and Outlook (2014-2024)
          • 1.4.1.2 Canada Market States and Outlook (2014-2024)
          • 1.4.1.3 Mexico Market States and Outlook (2014-2024)
        • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
          • 1.4.2.1 Germany Market States and Outlook (2014-2024)
          • 1.4.2.2 France Market States and Outlook (2014-2024)
          • 1.4.2.3 UK Market States and Outlook (2014-2024)
          • 1.4.2.4 Russia Market States and Outlook (2014-2024)
          • 1.4.2.5 Italy Market States and Outlook (2014-2024)
        • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
          • 1.4.3.1 China Market States and Outlook (2014-2024)
          • 1.4.3.2 Japan Market States and Outlook (2014-2024)
          • 1.4.3.3 Korea Market States and Outlook (2014-2024)
          • 1.4.3.4 India Market States and Outlook (2014-2024)
          • 1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
        • 1.4.4 South America, Middle East and Africa
          • 1.4.4.1 Brazil Market States and Outlook (2014-2024)
          • 1.4.4.2 Egypt Market States and Outlook (2014-2024)
          • 1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
          • 1.4.4.4 South Africa Market States and Outlook (2014-2024)
          • 1.4.4.5 Turkey Market States and Outlook (2014-2024)
      • 1.5 Market Dynamics
        • 1.5.1 Market Opportunities
        • 1.5.2 Market Risk
        • 1.5.3 Market Driving Force

      2 Manufacturers Profiles

      • 2.1 Pfizer
        • 2.1.1 Business Overview
        • 2.1.2 Tyrosine Kinase JAK Inhibitors Type and Applications
          • 2.1.2.1 Product A
          • 2.1.2.2 Product B
        • 2.1.3 Pfizer Tyrosine Kinase JAK Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
      • 2.2 Incyte
        • 2.2.1 Business Overview
        • 2.2.2 Tyrosine Kinase JAK Inhibitors Type and Applications
          • 2.2.2.1 Product A
          • 2.2.2.2 Product B
        • 2.2.3 Incyte Tyrosine Kinase JAK Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
      • 2.3 Novartis
        • 2.3.1 Business Overview
        • 2.3.2 Tyrosine Kinase JAK Inhibitors Type and Applications
          • 2.3.2.1 Product A
          • 2.3.2.2 Product B
        • 2.3.3 Novartis Tyrosine Kinase JAK Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
      • 2.4 Eli Lilly
        • 2.4.1 Business Overview
        • 2.4.2 Tyrosine Kinase JAK Inhibitors Type and Applications
          • 2.4.2.1 Product A
          • 2.4.2.2 Product B
        • 2.4.3 Eli Lilly Tyrosine Kinase JAK Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
      • 2.5 Gilead
        • 2.5.1 Business Overview
        • 2.5.2 Tyrosine Kinase JAK Inhibitors Type and Applications
          • 2.5.2.1 Product A
          • 2.5.2.2 Product B
        • 2.5.3 Gilead Tyrosine Kinase JAK Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
      • 2.6 Sanofi
        • 2.6.1 Business Overview
        • 2.6.2 Tyrosine Kinase JAK Inhibitors Type and Applications
          • 2.6.2.1 Product A
          • 2.6.2.2 Product B
        • 2.6.3 Sanofi Tyrosine Kinase JAK Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
      • 2.7 Galapagos
        • 2.7.1 Business Overview
        • 2.7.2 Tyrosine Kinase JAK Inhibitors Type and Applications
          • 2.7.2.1 Product A
          • 2.7.2.2 Product B
        • 2.7.3 Galapagos Tyrosine Kinase JAK Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
      • 2.8 AbbVie
        • 2.8.1 Business Overview
        • 2.8.2 Tyrosine Kinase JAK Inhibitors Type and Applications
          • 2.8.2.1 Product A
          • 2.8.2.2 Product B
        • 2.8.3 AbbVie Tyrosine Kinase JAK Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
      • 2.9 Vertex
        • 2.9.1 Business Overview
        • 2.9.2 Tyrosine Kinase JAK Inhibitors Type and Applications
          • 2.9.2.1 Product A
          • 2.9.2.2 Product B
        • 2.9.3 Vertex Tyrosine Kinase JAK Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
      • 2.10 Teva
        • 2.10.1 Business Overview
        • 2.10.2 Tyrosine Kinase JAK Inhibitors Type and Applications
          • 2.10.2.1 Product A
          • 2.10.2.2 Product B
        • 2.10.3 Teva Tyrosine Kinase JAK Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
      • 2.11 Astellas Pharma
        • 2.11.1 Business Overview
        • 2.11.2 Tyrosine Kinase JAK Inhibitors Type and Applications
          • 2.11.2.1 Product A
          • 2.11.2.2 Product B
        • 2.11.3 Astellas Pharma Tyrosine Kinase JAK Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
      • 2.12 Celgene
        • 2.12.1 Business Overview
        • 2.12.2 Tyrosine Kinase JAK Inhibitors Type and Applications
          • 2.12.2.1 Product A
          • 2.12.2.2 Product B
        • 2.12.3 Celgene Tyrosine Kinase JAK Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
      • 2.13 CTI BioPharma
        • 2.13.1 Business Overview
        • 2.13.2 Tyrosine Kinase JAK Inhibitors Type and Applications
          • 2.13.2.1 Product A
          • 2.13.2.2 Product B
        • 2.13.3 CTI BioPharma Tyrosine Kinase JAK Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)

      3 Global Tyrosine Kinase JAK Inhibitors Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

      • 3.1 Global Tyrosine Kinase JAK Inhibitors Sales and Market Share by Manufacturer (2017-2018)
      • 3.2 Global Tyrosine Kinase JAK Inhibitors Revenue and Market Share by Manufacturer (2017-2018)
      • 3.3 Market Concentration Rate
        • 3.3.1 Top 3 Tyrosine Kinase JAK Inhibitors Manufacturer Market Share in 2018
        • 3.3.2 Top 6 Tyrosine Kinase JAK Inhibitors Manufacturer Market Share in 2018
      • 3.4 Market Competition Trend

      4 Global Tyrosine Kinase JAK Inhibitors Market Analysis by Regions

      • 4.1 Global Tyrosine Kinase JAK Inhibitors Sales, Revenue and Market Share by Regions
        • 4.1.1 Global Tyrosine Kinase JAK Inhibitors Sales and Market Share by Regions (2014-2019)
        • 4.1.2 Global Tyrosine Kinase JAK Inhibitors Revenue and Market Share by Regions (2014-2019)
      • 4.2 North America Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 4.3 Europe Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 4.4 Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 4.5 South America Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 4.6 Middle East and Africa Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)

      5 North America Tyrosine Kinase JAK Inhibitors by Country

      • 5.1 North America Tyrosine Kinase JAK Inhibitors Sales, Revenue and Market Share by Country
        • 5.1.1 North America Tyrosine Kinase JAK Inhibitors Sales and Market Share by Country (2014-2019)
        • 5.1.2 North America Tyrosine Kinase JAK Inhibitors Revenue and Market Share by Country (2014-2019)
      • 5.2 United States Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 5.3 Canada Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 5.4 Mexico Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)

      6 Europe Tyrosine Kinase JAK Inhibitors by Country

      • 6.1 Europe Tyrosine Kinase JAK Inhibitors Sales, Revenue and Market Share by Country
        • 6.1.1 Europe Tyrosine Kinase JAK Inhibitors Sales and Market Share by Country (2014-2019)
        • 6.1.2 Europe Tyrosine Kinase JAK Inhibitors Revenue and Market Share by Country (2014-2019)
      • 6.2 Germany Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 6.3 UK Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 6.4 France Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 6.5 Russia Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 6.6 Italy Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)

      7 Asia-Pacific Tyrosine Kinase JAK Inhibitors by Country

      • 7.1 Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales, Revenue and Market Share by Country
        • 7.1.1 Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales and Market Share by Country (2014-2019)
        • 7.1.2 Asia-Pacific Tyrosine Kinase JAK Inhibitors Revenue and Market Share by Country (2014-2019)
      • 7.2 China Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 7.3 Japan Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 7.4 Korea Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 7.5 India Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 7.6 Southeast Asia Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)

      8 South America Tyrosine Kinase JAK Inhibitors by Country

      • 8.1 South America Tyrosine Kinase JAK Inhibitors Sales, Revenue and Market Share by Country
        • 8.1.1 South America Tyrosine Kinase JAK Inhibitors Sales and Market Share by Country (2014-2019)
        • 8.1.2 South America Tyrosine Kinase JAK Inhibitors Revenue and Market Share by Country (2014-2019)
      • 8.2 Brazil Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 8.3 Argentina Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 8.4 Colombia Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)

      9 Middle East and Africa Tyrosine Kinase JAK Inhibitors by Countries

      • 9.1 Middle East and Africa Tyrosine Kinase JAK Inhibitors Sales, Revenue and Market Share by Country
        • 9.1.1 Middle East and Africa Tyrosine Kinase JAK Inhibitors Sales and Market Share by Country (2014-2019)
        • 9.1.2 Middle East and Africa Tyrosine Kinase JAK Inhibitors Revenue and Market Share by Country (2014-2019)
      • 9.2 Saudi Arabia Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 9.3 Turkey Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 9.4 Egypt Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 9.5 Nigeria Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)
      • 9.6 South Africa Tyrosine Kinase JAK Inhibitors Sales and Growth Rate (2014-2019)

      10 Global Tyrosine Kinase JAK Inhibitors Market Segment by Type

      • 10.1 Global Tyrosine Kinase JAK Inhibitors Sales, Revenue and Market Share by Type (2014-2019)
        • 10.1.1 Global Tyrosine Kinase JAK Inhibitors Sales and Market Share by Type (2014-2019)
        • 10.1.2 Global Tyrosine Kinase JAK Inhibitors Revenue and Market Share by Type (2014-2019)
      • 10.2 Tofacitinib Sales Growth and Price
        • 10.2.1 Global Tofacitinib Sales Growth (2014-2019)
        • 10.2.2 Global Tofacitinib Price (2014-2019)
      • 10.3 Ruxolitinib Sales Growth and Price
        • 10.3.1 Global Ruxolitinib Sales Growth (2014-2019)
        • 10.3.2 Global Ruxolitinib Price (2014-2019)
      • 10.4 Baricitinib Sales Growth and Price
        • 10.4.1 Global Baricitinib Sales Growth (2014-2019)
        • 10.4.2 Global Baricitinib Price (2014-2019)

      11 Global Tyrosine Kinase JAK Inhibitors Market Segment by Application

      • 11.1 Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Application (2014-2019)
      • 11.2 Rheumatoid Arthritis (RA) Sales Growth (2014-2019)
      • 11.3 Polycythemia Vera (PCV) Sales Growth (2014-2019)
      • 11.4 Myelofibrosis (MF) Sales Growth (2014-2019)
      • 11.5 Others Sales Growth (2014-2019)

      12 Tyrosine Kinase JAK Inhibitors Market Forecast (2019-2024)

      • 12.1 Global Tyrosine Kinase JAK Inhibitors Sales, Revenue and Growth Rate (2019-2024)
      • 12.2 Tyrosine Kinase JAK Inhibitors Market Forecast by Regions (2019-2024)
        • 12.2.1 North America Tyrosine Kinase JAK Inhibitors Market Forecast (2019-2024)
        • 12.2.2 Europe Tyrosine Kinase JAK Inhibitors Market Forecast (2019-2024)
        • 12.2.3 Asia-Pacific Tyrosine Kinase JAK Inhibitors Market Forecast (2019-2024)
        • 12.2.4 South America Tyrosine Kinase JAK Inhibitors Market Forecast (2019-2024)
        • 12.2.5 Middle East and Africa Tyrosine Kinase JAK Inhibitors Market Forecast (2019-2024)
      • 12.3 Tyrosine Kinase JAK Inhibitors Market Forecast by Type (2019-2024)
        • 12.3.1 Global Tyrosine Kinase JAK Inhibitors Sales Forecast by Type (2019-2024)
        • 12.3.2 Global Tyrosine Kinase JAK Inhibitors Market Share Forecast by Type (2019-2024)
      • 12.4 Tyrosine Kinase JAK Inhibitors Market Forecast by Application (2019-2024)
        • 12.4.1 Global Tyrosine Kinase JAK Inhibitors Sales Forecast by Application (2019-2024)
        • 12.4.2 Global Tyrosine Kinase JAK Inhibitors Market Share Forecast by Application (2019-2024)

      13 Sales Channel, Distributors, Traders and Dealers

      • 13.1 Sales Channel
        • 13.1.1 Direct Marketing
        • 13.1.2 Indirect Marketing
        • 13.1.3 Marketing Channel Future Trend
      • 13.2 Distributors, Traders and Dealers

      14 Research Findings and Conclusion

        15 Appendix

        • 15.1 Methodology

        Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.

        These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.

        In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.

        Scope of the Report:
        Tyrosine Kinase JAK Inhibitors is widely used in Rheumatoid Arthritis (RA), Polycythemia Vera (PCV) and Myelofibrosis (MF). The most proportion of Tyrosine Kinase JAK Inhibitors is for Rheumatoid Arthritis (RA), and the proportion in 2017 is about 37%.
        North America is the largest consumption place, with a consumption market share nearly 56% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 39%.
        The worldwide market for Tyrosine Kinase JAK Inhibitors is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
        This report focuses on the Tyrosine Kinase JAK Inhibitors in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

        Market Segment by Manufacturers, this report covers
        Pfizer
        Incyte
        Novartis
        Eli Lilly
        Gilead
        Sanofi
        Galapagos
        AbbVie
        Vertex
        Teva
        Astellas Pharma
        Celgene
        CTI BioPharma

        Market Segment by Regions, regional analysis covers
        North America (United States, Canada and Mexico)
        Europe (Germany, France, UK, Russia and Italy)
        Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
        South America (Brazil, Argentina, Colombia etc.)
        Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

        Market Segment by Type, covers
        Tofacitinib
        Ruxolitinib
        Baricitinib

        Market Segment by Applications, can be divided into
        Rheumatoid Arthritis (RA)
        Polycythemia Vera (PCV)
        Myelofibrosis (MF)
        Others

        The content of the study subjects, includes a total of 15 chapters:
        Chapter 1, to describe Tyrosine Kinase JAK Inhibitors product scope, market overview, market opportunities, market driving force and market risks.
        Chapter 2, to profile the top manufacturers of Tyrosine Kinase JAK Inhibitors, with price, sales, revenue and global market share of Tyrosine Kinase JAK Inhibitors in 2017 and 2018.
        Chapter 3, the Tyrosine Kinase JAK Inhibitors competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
        Chapter 4, the Tyrosine Kinase JAK Inhibitors breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
        Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
        Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
        Chapter 12, Tyrosine Kinase JAK Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
        Chapter 13, 14 and 15, to describe Tyrosine Kinase JAK Inhibitors sales channel, distributors, customers, research findings and conclusion, appendix and data source.



        Summary:
        Tyrosine Kinase JAK Inhibitors Market Research Report is Tyrosine Kinase JAK Inhibitors Market Report. Get Tyrosine Kinase JAK Inhibitors market research reports for Market Research, Analysis, Trends & Statistics. Latest Industry findings, analysis and Market Report on Tyrosine Kinase JAK Inhibitors. Tyrosine Kinase JAK Inhibitors Market Report is a syndicated market report to understand, Market Demand, Growth, trends analysis and Factor Influencing market in upcoming years.



        REPORT YOU MIGHT BE INTERESTED